Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ramipril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 12/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.96 |
| ▸ | USP2 | O75604 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ramipril SCHEMBL7260219 | 1.00 | ACE (1.00) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramipril SCHEMBL7912384 | 1.00 | ACE (1.00) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramipril SCHEMBL13575807 | 1.00 | ACE (1.00) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramipril SCHEMBL9175613 | 1.00 | ACE (1.00) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramipril SCHEMBL9327932 | 1.00 | ACE (1.00) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramipril SCHEMBL8082369 | 1.00 | ACE (1.00) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramipril SCHEMBL683419 | 1.00 | ACE (1.00) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramipril SCHEMBL16059 | 1.00 | ACE (1.00) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramipril SCHEMBL13780690 | 1.00 | ACE (1.00) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramipril SCHEMBL5983968 | 1.00 | ACE (1.00) | ACEMEN1KMT2ACYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022083644-A1 | BIOSENSING PLATFORM FOR DETECTING VIRAL INFECTIONS AND METHODS FOR SCREENING A MODULATOR OF VIRAL INFECTIONS AND PROTECTING THEREFROM | PD BIOMEDICAL CO., LTD. (CN) | 2022-04-28 | — | — | WO | disclosed |
| US-20220117936-A1 | BIOSENSING PLATFORM FOR DETECTING VIRAL INFECTIONS AND METHODS FOR SCREENING A MODULATOR OF VIRAL INFECTIONS AND PROTECTING THEREFROM | PIN JYE BIO TECH CO., LTD. (TW) | 2022-04-21 | — | — | US | disclosed |
| US-9730949-B2 | Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy | REKIK RAOUF (TN) | 2017-08-15 | — | — | US | disclosed |
| US-9730949-B2 | Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy | REKIK RAOUF (TN) | 2017-08-15 | — | — | US | disclosed |
| US-20150174146-A1 | ANGIOTENSIN CONVERTING ENZYME INHIBITORS FOR TREATING OPTIC NEUROPATHY OR CONGENITAL OPTIC ATROPHY | REKIK RAOUF (TN) | 2015-06-25 | — | — | US | disclosed |
| US-20150174146-A1 | ANGIOTENSIN CONVERTING ENZYME INHIBITORS FOR TREATING OPTIC NEUROPATHY OR CONGENITAL OPTIC ATROPHY | REKIK RAOUF (TN) | 2015-06-25 | — | — | US | disclosed |
| EP-2044010-B1 | NEW PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INIHIBITORS AND THE USE THEREOF | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDO RESZVENYTARSASAG (HU) | 2014-01-08 | — | — | EP | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7960558-B2 | Pharmaceutical intermediate for synthesizing ACE inhibitors and the use thereof | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2011-06-14 | — | — | US | disclosed |
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7858611-B2 | Neurogenesis by modulating angiotensin | BRAINCELLS INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100286404-A1 | PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INHIBITORS AND THE USE THEREOF | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-11-11 | — | — | US | disclosed |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-5068351-A | PROCESS FOR THE PREPARATION OF N OCTAHYDROPENTA (6) PYRROLE CARBOXYLATES | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286404-A1 | PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INHIBITORS AND THE USE THEREOF | ACE, AGTR1, REN | ACE 1/4885MEN1 3814/4885KMT2A 4114/4885 |
| US-20150174146-A1 | ANGIOTENSIN CONVERTING ENZYME INHIBITORS FOR TREATING OPTIC NEUROPATHY OR CONGENITAL OPTIC ATROPHY | ACE, ACE2, AGT | ACE 1/4885MEN1 3080/4885KMT2A 3900/4885 |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | ACE 4514/4885MEN1 3647/4885KMT2A 2044/4885 |
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | ACE 10/4885MEN1 2541/4885KMT2A 2068/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ACE 6/4885MEN1 1910/4885KMT2A 1893/4885 |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | MMP1, COL2A1, FN1 | ACE 2888/4885MEN1 3324/4885KMT2A 3542/4885 |
| US-20220117936-A1 | BIOSENSING PLATFORM FOR DETECTING VIRAL INFECTIONS AND METHODS FOR SCREENING A MODULATOR OF VIRAL INFECTIONS AND PROTECTING THEREFROM | ACE2, ACE, TMPRSS2 | ACE 2/4885MEN1 4392/4885KMT2A 4152/4885 |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | ACE 10/4885MEN1 2535/4885KMT2A 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.